Evidence map›Paper›PMID 39504843›Full record

ArticleChemosphere2024

Corrigendum to "Evaluation of 14 PFAS for permeability and organic anion transporter interactions: Implications for renal clearance in humans" [Chemosphere 361 August 2024, 1-9, 142390].

Sangwoo Ryu, Emi Yamaguchi, Seyed Mohamad Sadegh Modaresi, Juliana Agudelo, Chester Costales, Mark A West, Fabian Fischer, Angela L Slitt

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Chemosphere, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Sangwoo RyuDepartment of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, RI, 02881, United States; Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, Pfizer Inc., Groton, CT, 06340, United States.
Emi YamaguchiPharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, Pfizer Inc., Groton, CT, 06340, United States.
Seyed Mohamad Sadegh ModaresiDepartment of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, RI, 02881, United States.
Juliana AgudeloDepartment of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, RI, 02881, United States.
Chester CostalesPharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, Pfizer Inc., Groton, CT, 06340, United States.
Mark A WestPharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, Pfizer Inc., Groton, CT, 06340, United States.
Fabian FischerDepartment of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, RI, 02881, United States; Harvard John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA, 02138, United States. Electronic address: fabian.fischer@uri.edu.
Angela L SlittDepartment of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, RI, 02881, United States. Electronic address: aslitt@uri.edu.

Funding

Sources, Transport, Exposure & Effects of PFAS (STEEP) Center - RENEWALP42ES027706 · NIEHS · UNIVERSITY OF RHODE ISLAND · PI Rainer Lohmann · 2017 to 2026
$18.9M
NIEHS NIH HHS P42 ES027706
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39504843
PMCPMC11825105

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.